



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

August 24, 2015

Via E-mail

Mr. Michael Kalb

Group Vice President, Chief Financial Officer and Chief Accounting Officer

Taro Pharmaceutical Industries Ltd.

3 Skyline Drive

Hawthorne, NY 10532

Re: Taro Pharmaceutical Industries Ltd.
Form 20-F for the Fiscal Year Ended March 31, 2015
Filed July 1, 2015
File No. 001-35463

Dear Mr. Kalb:

We have completed our review of your filing. We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require.

Sincerely,

/s/ Sharon Blume

Sharon Blume
Accounting Branch Chief